The body keeps the appointment
Trauma is not only a memory problem. Understanding why it lives in the body helps explain why some emerging therapies work on the body's terms, not the mind's alone.
One of the most useful shifts in trauma science over the past few decades is the recognition that trauma is not stored the way a diary is. The title of this essay borrows from Bessel van der Kolk's The Body Keeps the Score, the book that carried that idea into ordinary conversation. The careful version of the claim is not that memories are stored in the muscles. It is that the brain's threat-detection systems learn from overwhelming experience and stay on duty long after it — a body braced for a danger that has, in fact, already passed.
Why "just talk about it" can fail
Talking, reasoning and reassurance mostly engage the parts of the brain that work slowly and deliberately. Much of what trauma does happens in older, faster systems built to act first and ask questions never. This is why a person can understand, intellectually, that they are safe and still find their heart racing at a sound, a smell, a date on a calendar. The knowing and the bracing live in different places.
Recovery is not persuading the mind that the danger is over. It is persuading the body.
This is not an argument against talking therapies. Trauma-focused psychotherapies such as prolonged exposure and EMDR remain the best-supported treatments for post-traumatic stress, and they work partly by helping the body learn, through repeated safe contact with the memory, that the alarm can stand down. The point is that they work by changing a response, not by winning an argument.
Where new approaches fit
MDMA-assisted therapy for PTSD is interesting precisely because it appears to change the conditions under which a memory can be approached — lowering the alarm enough that the experience can be revisited without the body slamming the door. The therapy does the work; the drug, in this account, widens the window in which the work is bearable.
The evidence is real but unfinished. Two Phase 3 trials, with 90 and 104 participants, found that around two-thirds of people who received MDMA with therapy no longer met criteria for PTSD afterwards, compared with roughly a third to a half of those who received therapy with placebo. In 2024 the US Food and Drug Administration nonetheless declined to approve the treatment, citing concerns about blinding, the reporting of harms, and how the therapy component could be standardised, and asked for a further trial. The mechanism described above is a hypothesis under investigation, not a settled fact. But it points at something clinicians have long observed: people can often only process what they are not, in that moment, drowning in.
What this means for expectations
- The aim is not erasure of memory but a changed relationship to it.
- Bodily safety — pacing, grounding, a trusted person present — is not optional in any trauma treatment, with or without a drug.
- Progress is frequently non-linear, and a hard week is not a failed treatment.
The body kept the appointment for years. Healing tends to mean, at last, being allowed to leave the waiting room.
Sources and further reading
- van der Kolk B. The Body Keeps the Score. Viking, 2014.
- Mitchell JM et al. "MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study." Nature Medicine, 2021.
- Mitchell JM et al. "MDMA-assisted therapy for moderate to severe PTSD: a randomized, double-blind, placebo-controlled phase 3 trial." Nature Medicine, 2023.
- US FDA advisory committee meeting on midomafetamine (MDMA) for PTSD, June 2024, and subsequent complete response letter, August 2024.
- Lewis C et al. "Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis." European Journal of Psychotraumatology, 2020.
This essay is general information, not medical advice.